A Phase 3 interventional study of placebo and iv sildenafil in Pulmonary Hypertension, Familial Persistent, of the Newborn, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 42 sites in 12 countries. Open to participants aged 0 Days to 4 Days. Per ClinicalTrials.gov, last updated 2021-08-16.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Persistent Fetal Circulation Syndrome · United States.
Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 12th registered.
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
Browse Persistent Fetal Circulation Syndrome studies →1 of the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States is open now. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages up to 12 mo · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Persistent Fetal Circulation Syndrome studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 0 Days to 4 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.
Median enrollment 38 across the 12 interventional studies, 106 across the 4 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 3 studies filed under Persistent Fetal Circulation Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
iv placebo of normal saline or 10% dextrose
Drug: placebo
Active study drug
Drug: iv sildenafil
IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
Also known as: revatio
Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure
Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Treatment Failure Rate
Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation
Time in days, from initiation of IV study drug to final weaning of mechanical ventilation among participants achieving final weaning of mechanical ventilation for PPHN was evaluated. Kaplan-Meier method was used for estimation. For participants with mechanical ventilation beyond 336 hours (14 days) from initiation of IV study drug, data was censored at 14 days.
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure
Time in days, from initiation of IV study drug to first treatment failure (defined as need for additional treatment targeting PPHN, need for ECMO, or death) for participants with treatment failure was evaluated. Kaplan-Meier method was used for estimation. For participants without treatment failure by the endpoint assessment date, data was censored at the endpoint assessment date.
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Percentage of Participants With Individual Components of Treatment Failure
Percentage of participants with individual components of treatment failure (need to start additional treatment targeting PPHN, need to start ECMO, or death) were evaluated. Some participants could have had multiple qualifying events for treatment failure.
Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Change From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion
Oxygenation index was calculated as the product of fraction of inspired oxygen (FiO2) and mean airway pressure divided by partial pressure of oxygen dissolved in arterial blood (PaO2) \[(FiO2\*mean airway pressure)/PaO2\] measured in centimeter of water per millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level dissolved in the arterial blood.
Time frame: Baseline, Hours 6, 12 and 24 after start of infusion
Change From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion
Differential oxygenation saturation is a simple way to detect the right-to left shunting at ductus arteriosus using 2 pulse oximeters. It is the difference between pre-ductal and post-ductal sites pulse oxygen saturation (SpO2). Where, pre-duct refers to right upper extremity and post-duct refers to lower limb. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood.
Time frame: Baseline, Hours 6, 12 and 24 after start of infusion
Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24
The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen is a ratio between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood.
Time frame: Baseline, Hours 6, 12 and 24 after start of infusion
Maximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite
Cmax was obtained for Sildenafil and its major metabolite UK-103,320.
Time frame: Loading dose, Day 1: prior to the start of infusion, 5, 30 minutes after end of loading infusion; Maintenance dose: 48 to 72, 96 to 120 hours during infusion and immediately prior to end of maintenance infusion (up to maximum on Day 14)
Total Plasma Clearance (CL) of Sildenafil and Its Metabolite
CL is volume of the body fluid/ plasma from which the drug or the metabolite is completely removed per unit time. CL was obtained for Sildenafil and its major metabolite UK-103,320.
Time frame: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Central Volume of Distribution (Vc) of Sildenafil and Its Metabolite
Vc is the hypothetical volume into which a drug or a metabolite initially distributes upon administration. It was determined by using a population-based analysis, non-linear mixed-effects modeling (NONMEM), version 7.4.0. Vc was calculated for Sildenafil and its major metabolite, UK-103,320.
Time frame: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
Time frame: Baseline up to 31 days after end of study drug infusion (up to 45 days)
Number of Treatment-Emergent Adverse Events (AEs) According to Severity
AE: untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Severity criteria: mild=did not interfere with subject's usual function; moderate=interfered to some extent with participant's usual function and severe=interfered significantly with participant's usual function. Missing baseline severities were imputed as mild.
Time frame: Baseline up to 31 days after end of study drug infusion (up to 45 days)
Number of Participants With Laboratory Abnormalities
Criteria for laboratory values: Hematology: hemoglobin, hematocrit, red blood cell count \<0.8\*lower limit of normal (LLN), platelets\<0.5\*LLN, \>1.75\*upper limit of normal (ULN), white blood cells count \<0.6\*LLN, \>1.5\*ULN; Liver function: total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein \<0.8\*LLN, \>1.2\*ULN; Renal function: blood urea nitrogen, creatinine \>1.3\*ULN; Electrolytes: sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride, calcium, bicarbonate (venous) \<0.9\*LLN, \>1.1\*ULN.
Time frame: Up to 14 days from initiation of study drug infusion
Part B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. Score ranges: cognitive scale 0-91, language scale 0-97 and motor scale 0-132, where higher scores indicated better cognitive function, communication and motor skills respectively. Raw scores of cognitive, language and motor domains were converted to composite scores. Composite scores of cognitive, language and motor developmental scales ranged from a scale of 40 to 160, where higher score indicated stronger skills and abilities. In this outcome measure composite scores for infants and toddlers were reported at month 12 and 24.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
The Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. The questionnaire comprises the SE scale (35 items) and the AB scale (241 items). Raw scores of SE and AB were converted to composite scores. Composite scores for SE and AB scale ranged from 40 to 160, where higher scores indicated better social-emotional skills and adaptive behavior in child. In this outcome measure composite scores for parent/caregiver were reported at month 24.
Time frame: Month 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination
Standard age-appropriate ophthalmological examinations were used to assess eye movement disorders (presence of amblyopia, strabismus, and nystagmus) at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to eye movement disorder categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) through visual acuity chart (VAC) quantitative, counting finger (CF), hand motion (HM), light perception (LP), no light perception (NLP) and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children unable of verbal interaction) through fixates and follows (included central, steady and maintained), light perception (wince to light), no light perception, and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) at month 12 and 24. Visual acuity (VA) of verbal children was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal, logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments
Standard age-appropriate ophthalmological examinations were used to assess examination of anterior and posterior chamber for abnormality in lids, conjunctiva, cornea, anterior chamber, lens, iris, pupil, extraocular muscle movement and eye movements at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual status categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported using behavior hearing assessment through pure tone audiometry test which includes participants with normal, abnormal, incomplete/inconclusive behavior at month 12 and 24.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported by bone conduction assessment through pure tone audiometry test which included participants with sensorineural hearing loss, conductive hearing loss, mixed hearing loss, neural, and unspecified at month 12 and 24. Rows according to bone conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported by air conduction via phones/headphones through pure tone audiometry test which included participants with hearing loss ranged from less than or equal to (\<=) 20 decibel hearing loss (DB HL), 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, greater than (\>) 90 DB HL or no response, and missing at frequencies ranged from 500 Hertz (Hz) to 8000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test
Audiological evaluations of participants were recorded and reported by air conduction via soundfield through pure tone audiometry test which included participants with hearing loss ranged from \<=20 DB HL, 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, \>90 DB HL or no response, and missing at frequencies ranged from 500 Hz to 4000 Hz at month 12 and 24. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test
Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with peak pressure signs (+) and (-) at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test
Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with static acoustic admittance at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test
Audiological evaluations of participants were recorded and reported by ipsilateral stapedial reflex through immittance audiometry test which included participants with presence of ipsilateral stapedial reflex at frequencies ranged from 500 Hz to 2000 Hz at month 12 and 24. Ipsilateral stapedial reflex measures are used to assess the neural pathway surrounding the stapedial reflex, which occurs in response to a loud sound (70 to 90 decibel above threshold). In this outcome measure, data have been reported for right and left ear separately.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment
Audiological evaluations of participants were recorded and reported by transient evoked emission through otoacoustic emissions assessment which included participants with presence of transient evoked emissions from frequencies 1000 Hz to 4000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment
Audiological evaluations of participants were recorded and reported by distort product through otoacoustic emissions assessment which included participants with presence of distort product at frequencies ranged from 2000 Hz to 8000 Hz at month 12 and 24. Distortion-product otoacoustic emissions (DPOAEs) are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal. Distort product otoacoustic emissions are an objective indicator of normally functioning cochlea outer hair cells. In this outcome measure, data have been reported for right and left ear separately.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths
An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.
Time frame: up to 24 months after end of study treatment in Part A (maximum up to 26 months)
Part B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score
The Hammersmith Infant Neurological Examination (HINE) was a standard scoring examination to assess development of cranial nerve; posture; movement; tone; and reflexes and reaction. HINE exam global score is a sum of subset (cranial nerve, posture, movement, tone, reflexes and reactions) scores, ranged from 0 to 78, where higher score represents better outcome. Here, the HINE global scores were reported at month 12 and 24.
Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).
| Milestone | IV Sildenafil | Placebo |
|---|---|---|
| Started | 29 | 30 |
| Completed | 22 | 18 |
| Not completed | 7 | 12 |
| Withdrew: Insufficient clinical response | 2 | 4 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Missed 28 day follow-up visit | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | IV Sildenafil | Placebo |
|---|---|---|
| Started | 27 | 26 |
| Completed | 22 | 17 |
| Not completed | 5 | 9 |
| Withdrew: No longer willing to participate in study | 1 | 4 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Death | 0 | 2 |
Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.
| days | IV Sildenafil | Placebo |
|---|---|---|
| Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure | 4.1 (2.58 to 5.58) | 4.1 (2.70 to 5.50) |
Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.
| percentage of participants | IV Sildenafil | Placebo |
|---|---|---|
| Treatment Failure Rate | 27.6 (11.3 to 43.9) | 20.0 (5.7 to 34.3) |
Time in days, from initiation of IV study drug to final weaning of mechanical ventilation among participants achieving final weaning of mechanical ventilation for PPHN was evaluated. Kaplan-Meier method was used for estimation. For participants with mechanical ventilation beyond 336 hours (14 days) from initiation of IV study drug, data was censored at 14 days.
| days | IV Sildenafil | Placebo |
|---|---|---|
| Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation | 8.3 (5.46 to 11.75) | 7.3 (5.46 to 10.78) |
Time in days, from initiation of IV study drug to first treatment failure (defined as need for additional treatment targeting PPHN, need for ECMO, or death) for participants with treatment failure was evaluated. Kaplan-Meier method was used for estimation. For participants without treatment failure by the endpoint assessment date, data was censored at the endpoint assessment date.
| days | IV Sildenafil | Placebo |
|---|---|---|
| Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure | NA (NA to NA) | NA (NA to NA) |
Percentage of participants with individual components of treatment failure (need to start additional treatment targeting PPHN, need to start ECMO, or death) were evaluated. Some participants could have had multiple qualifying events for treatment failure.
| percentage of participants | IV Sildenafil | Placebo |
|---|---|---|
| Additional Treatment Targeting PPHN | 13.8 (3.9 to 31.7) | 10.0 (2.1 to 26.5) |
| ECMO | 10.3 (2.2 to 27.4) | 10.0 (2.1 to 26.5) |
| Death | 6.9 (0.8 to 22.8) | 0.0 (0.0 to 11.6) |
Oxygenation index was calculated as the product of fraction of inspired oxygen (FiO2) and mean airway pressure divided by partial pressure of oxygen dissolved in arterial blood (PaO2) \[(FiO2\*mean airway pressure)/PaO2\] measured in centimeter of water per millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level dissolved in the arterial blood.
| cmH2O/mmHg | IV Sildenafil | Placebo |
|---|---|---|
| Change at Hour 6 | -4.2 (-11.64 to 3.34) | -8.0 (-16.63 to 0.57) |
| Change at Hour 12 | -4.1 (-10.51 to 2.23) | -8.2 (-15.42 to -1.04) |
| Change at Hour 24 | -11.6 (-15.40 to -7.83) | -9.5 (-13.36 to -5.57) |
Differential oxygenation saturation is a simple way to detect the right-to left shunting at ductus arteriosus using 2 pulse oximeters. It is the difference between pre-ductal and post-ductal sites pulse oxygen saturation (SpO2). Where, pre-duct refers to right upper extremity and post-duct refers to lower limb. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood.
| percentage of hemoglobin | IV Sildenafil | Placebo |
|---|---|---|
| Change at Hour 6 | 1.5 (-1.79 to 4.80) | 0.8 (-3.10 to 4.62) |
| Change at Hour 12 | -1.2 (-7.65 to 5.21) | 6.7 (-0.65 to 14.12) |
| Change at Hour 24 | 1.2 (-7.15 to 9.49) | 9.3 (-0.40 to 19.08) |
The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen is a ratio between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood.
| ratio | IV Sildenafil | Placebo |
|---|---|---|
| Change at Hour 6 | 45.3 (17.21 to 73.37) | 8.1 (-23.48 to 39.60) |
| Change at Hour 12 | 43.4 (16.76 to 70.13) | 16.9 (-11.97 to 45.68) |
| Change at Hour 24 | 94.6 (18.52 to 170.69) | 14.7 (-67.83 to 97.25) |
Cmax was obtained for Sildenafil and its major metabolite UK-103,320.
| nanogram per milliliter | IV Sildenafil |
|---|---|
| Loading dose: Sildenafil | 52.64 ± 27.91 |
| Loading dose: UK-103320 | 1.04 ± 1.68 |
| Maintenance dose: Sildenafil | 78.12 ± 48.63 |
| Maintenance dose: UK-103320 | 21.65 ± 11.57 |
CL is volume of the body fluid/ plasma from which the drug or the metabolite is completely removed per unit time. CL was obtained for Sildenafil and its major metabolite UK-103,320.
| Liters/hour | IV Sildenafil |
|---|---|
| Sildenafil | 1.78 ± 0.89 |
| UK-103,320 | 5.05 ± 2.25 |
Vc is the hypothetical volume into which a drug or a metabolite initially distributes upon administration. It was determined by using a population-based analysis, non-linear mixed-effects modeling (NONMEM), version 7.4.0. Vc was calculated for Sildenafil and its major metabolite, UK-103,320.
| Liters | IV Sildenafil |
|---|---|
| Sildenafil | 8.76 ± 1.8 |
| UK-103,320 | 15.96 ± 11.20 |
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| AEs | 22 | 19 |
| SAEs | 7 | 2 |
AE: untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Severity criteria: mild=did not interfere with subject's usual function; moderate=interfered to some extent with participant's usual function and severe=interfered significantly with participant's usual function. Missing baseline severities were imputed as mild.
| events | IV Sildenafil | Placebo |
|---|---|---|
| Mild | 49 | 42 |
| Moderate | 29 | 24 |
| Severe | 12 | 17 |
Criteria for laboratory values: Hematology: hemoglobin, hematocrit, red blood cell count \<0.8\*lower limit of normal (LLN), platelets\<0.5\*LLN, \>1.75\*upper limit of normal (ULN), white blood cells count \<0.6\*LLN, \>1.5\*ULN; Liver function: total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein \<0.8\*LLN, \>1.2\*ULN; Renal function: blood urea nitrogen, creatinine \>1.3\*ULN; Electrolytes: sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride, calcium, bicarbonate (venous) \<0.9\*LLN, \>1.1\*ULN.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Number of Participants With Laboratory Abnormalities | 27 | 22 |
Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. Score ranges: cognitive scale 0-91, language scale 0-97 and motor scale 0-132, where higher scores indicated better cognitive function, communication and motor skills respectively. Raw scores of cognitive, language and motor domains were converted to composite scores. Composite scores of cognitive, language and motor developmental scales ranged from a scale of 40 to 160, where higher score indicated stronger skills and abilities. In this outcome measure composite scores for infants and toddlers were reported at month 12 and 24.
| units on a scale | IV Sildenafil | Placebo |
|---|---|---|
| Cognitive Development: Month 12 | 97.5 ± 16.14 | 94.5 ± 14.18 |
| Cognitive Development: Month 24 | 97.4 ± 18.12 | 97.3 ± 14.95 |
| Language Development: Month 12 | 99.5 ± 16.86 | 94.7 ± 10.25 |
| Language Development: Month 24 | 96.7 ± 21.91 | 95.8 ± 17.70 |
| Motor Development: Month 12 | 93.1 ± 16.10 | 88.2 ± 14.61 |
| Motor Development: Month 24 | 99.0 ± 19.59 | 105.3 ± 24.00 |
The Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. The questionnaire comprises the SE scale (35 items) and the AB scale (241 items). Raw scores of SE and AB were converted to composite scores. Composite scores for SE and AB scale ranged from 40 to 160, where higher scores indicated better social-emotional skills and adaptive behavior in child. In this outcome measure composite scores for parent/caregiver were reported at month 24.
| units on a scale | IV Sildenafil | Placebo |
|---|---|---|
| Social-Emotional Development | 104.5 ± 21.40 | 112.5 ± 18.13 |
| Adaptive Behavior Development | 91.6 ± 15.66 | 98.3 ± 12.44 |
Standard age-appropriate ophthalmological examinations were used to assess eye movement disorders (presence of amblyopia, strabismus, and nystagmus) at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to eye movement disorder categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Strabismus Present, Right Eye: Month 12 | 0 | 1 |
| Strabismus Present, Left Eye: Month 12 | 0 | 1 |
| Strabismus Present, Right Eye: Month 24 | 1 | 0 |
| Strabismus Present, Left Eye: Month 24 | 1 | 0 |
| Nystagmus Present, Left Eye: Month 24 | 0 | 1 |
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) through visual acuity chart (VAC) quantitative, counting finger (CF), hand motion (HM), light perception (LP), no light perception (NLP) and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| VAC Quantitative, Right Eye: Month 12 | 2 | 1 |
| HM, Right Eye: Month 12 | 0 | 2 |
| LP, Right Eye: Month 12 | 1 | 0 |
| Missing, Right Eye: Month 12 | 13 | 11 |
| VAC Quantitative, Left Eye: Month 12 | 2 | 1 |
| HM, Left Eye: Month 12 | 0 | 2 |
| LP, Left Eye: Month 12 | 1 | 0 |
| Missing, Left Eye: Month 12 | 13 | 11 |
| VAC Quantitative, Right Eye: Month 24 | 6 | 5 |
| HM, Right Eye: Month 24 | 1 | 0 |
| Missing, Right Eye: Month 24 | 5 | 7 |
| VAC Quantitative, Left Eye: Month 24 | 6 | 5 |
| Missing, Left Eye: Month 24 | 6 | 7 |
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children unable of verbal interaction) through fixates and follows (included central, steady and maintained), light perception (wince to light), no light perception, and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Fixates and Follows, Right Eye: Month 12 | 15 | 13 |
| Light Perception, Right Eye: Month 12 | 0 | 1 |
| Missing, Right Eye: Month 12 | 1 | 0 |
| Fixates and Follows, Left Eye: Month 12 | 15 | 13 |
| Light Perception, Left Eye: Month 12 | 0 | 1 |
| Missing, Left Eye: Month 12 | 1 | 0 |
| Fixates and Follows, Right Eye: Month 24 | 5 | 9 |
| Missing, Right Eye: Month 24 | 7 | 3 |
| Fixates and Follows, Left Eye: Month 24 | 5 | 9 |
| Missing, Left Eye: Month 24 | 7 | 3 |
Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) at month 12 and 24. Visual acuity (VA) of verbal children was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal, logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately.
| LogMAR | IV Sildenafil | Placebo |
|---|---|---|
| Right Eye: Month 12 | 0.45 ± 0.394 | 0.57 ± 0.513 |
| Left Eye: Month 12 | 0.47 ± 0.372 | 0.57 ± 0.513 |
| Right Eye: Month 24 | 0.20 ± 0.155 | 0.28 ± 0.299 |
| Left Eye: Month 24 | 0.20 ± 0.155 | 0.35 ± 0.409 |
Standard age-appropriate ophthalmological examinations were used to assess examination of anterior and posterior chamber for abnormality in lids, conjunctiva, cornea, anterior chamber, lens, iris, pupil, extraocular muscle movement and eye movements at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual status categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Anterior Segment (Lids), Right Eye: Month 12 | 0 | 1 |
| Anterior Segment (Lids), Left Eye: Month 12 | 0 | 1 |
| Anterior Segment (Extraocular muscle movements), Right Eye: Month 24 | 1 | 0 |
| Anterior Segment (Extraocular muscle movements), Left Eye: Month 24 | 1 | 0 |
Audiological evaluations of participants were recorded and reported using behavior hearing assessment through pure tone audiometry test which includes participants with normal, abnormal, incomplete/inconclusive behavior at month 12 and 24.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Normal Behavioral Assessment: Month 12 | 11 | 8 |
| Abnormal Behavioral Assessment: Month 12 | 1 | 4 |
| Incomplete/Inconclusive Behavioral Assessment: Month 12 | 4 | 0 |
| Normal Behavioral Assessment: Month 24 | 13 | 8 |
| Abnormal Behavioral Assessment: Month 24 | 0 | 2 |
| Incomplete/Inconclusive Behavioral Assessment: Month 24 | 3 | 2 |
Audiological evaluations of participants were recorded and reported by bone conduction assessment through pure tone audiometry test which included participants with sensorineural hearing loss, conductive hearing loss, mixed hearing loss, neural, and unspecified at month 12 and 24. Rows according to bone conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Conductive Hearing Loss: Month 12 | 0 | 1 |
| Unspecified: Month 12 | 1 | 1 |
| Conductive Hearing Loss: Month 24 | — | 1 |
Audiological evaluations of participants were recorded and reported by air conduction via phones/headphones through pure tone audiometry test which included participants with hearing loss ranged from less than or equal to (\<=) 20 decibel hearing loss (DB HL), 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, greater than (\>) 90 DB HL or no response, and missing at frequencies ranged from 500 Hertz (Hz) to 8000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| Right Ear, 500 Hz, <=20 DB HL: Month 12 | 3 | 4 |
| Right Ear, 500 Hz, 21 - 40 DB HL: Month 12 | 2 | 1 |
| Right Ear, 1000 Hz, <=20 DB HL: Month 12 | 4 | 5 |
| Right Ear, 1000 Hz, 21 - 40 DB HL: Month 12 | 1 | 0 |
| Right Ear, 2000 Hz, <=20 DB HL: Month 12 | 3 | 4 |
| Right Ear, 2000 Hz, 21 - 40 DB HL: Month 12 | 2 | 0 |
| Right Ear, 4000 Hz, <=20 DB HL: Month 12 | 4 | 5 |
| Right Ear, 4000 Hz, 21 - 40 DB HL: Month 12 | 1 | 0 |
| Right Ear, 8000 Hz, <=20 DB HL: Month 12 | 3 | 4 |
| Right Ear, 8000 Hz, Missing: Month 12 | 2 | 0 |
| Left Ear, 500 Hz, <=20 DB HL: Month 12 | 3 | 3 |
| Left Ear, 500 Hz, 21 - 40 DB HL: Month 12 | 2 | 1 |
| Left Ear, 1000 Hz, <=20 DB HL: Month 12 | 3 | 5 |
| Left Ear, 1000 Hz, 21 - 40 DB HL: Month 12 | 2 | 0 |
| Left Ear, 2000 Hz, <=20 DB HL: Month 12 | 3 | 4 |
| Left Ear, 2000 Hz, 21 - 40 DB HL: Month 12 | 2 | 0 |
| Left Ear, 4000 Hz, <=20 DB HL: Month 12 | 4 | 5 |
| Left Ear, 4000 Hz, 21 - 40 DB HL: Month 12 | 1 | 0 |
| Left Ear, 8000 Hz, <=20 DB HL: Month 12 | 3 | 4 |
| Left Ear, 8000 Hz, Missing: Month 12 | 2 | 1 |
| Right Ear, 500 Hz, <=20 DB HL: Month 24 | 5 | 3 |
| Right Ear, 500 Hz, 21-40 DB HL: Month 24 | 2 | 0 |
| Right Ear, 1000 Hz, <=20 DB HL: Month 24 | 5 | 2 |
| Right Ear, 1000 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Right Ear, 2000 Hz, <=20 DB HL: Month 24 | 6 | 3 |
| Right Ear, 2000 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Right Ear, 4000 Hz, <=20 DB HL: Month 24 | 7 | 3 |
| Right Ear, 8000 Hz, <=20 DB HL: Month 24 | 4 | 3 |
| Right Ear, 8000 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Right Ear, 8000 Hz, Missing: Month 24 | 1 | 0 |
| Left Ear, 500 Hz, <=20 DB HL: Month 24 | 6 | 3 |
| Left Ear, 500 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Left Ear, 1000 Hz, <=20 DB HL: Month 24 | 4 | 3 |
| Left Ear, 1000 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Left Ear, 2000 Hz, <=20 DB HL: Month 24 | 6 | 2 |
| Left Ear, 2000 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Left Ear, 4000 Hz, <=20 DB HL: Month 24 | 7 | 4 |
| Left Ear, 8000 Hz, <=20 DB HL: Month 24 | 3 | 3 |
| Left Ear, 8000 Hz, 21-40 DB HL: Month 24 | 1 | 0 |
| Left Ear, 8000 Hz, Missing: Month 24 | 1 | 0 |
Audiological evaluations of participants were recorded and reported by air conduction via soundfield through pure tone audiometry test which included participants with hearing loss ranged from \<=20 DB HL, 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, \>90 DB HL or no response, and missing at frequencies ranged from 500 Hz to 4000 Hz at month 12 and 24. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| 500 Hz, <=20 DB HL: Month 12 | 6 | 2 |
| 500 Hz, 21-40 DB HL: Month 12 | 5 | 6 |
| 500 Hz, 71-90 DB HL: Month 12 | 1 | 0 |
| 1000 Hz, <=20 DB HL: Month 12 | 9 | 3 |
| 1000 Hz, 21-40 DB HL: Month 12 | 1 | 5 |
| 1000 Hz, 71-90 DB HL: Month 12 | 1 | 0 |
| 2000 Hz, <=20 DB HL: Month 12 | 7 | 2 |
| 2000 Hz, 21-40 DB HL: Month 12 | 3 | 4 |
| 2000 Hz, Missing: Month 12 | 1 | 0 |
| 4000 Hz, <=20 DB HL: Month 12 | 6 | 4 |
| 4000 Hz, 21-40 DB HL: Month 12 | 4 | 4 |
| 4000 Hz, 71-90 DB HL: Month 12 | 1 | 0 |
| 500 Hz, <=20 DB HL: Month 24 | 6 | 2 |
| 500 Hz, 21-40 DB HL: Month 24 | 2 | 5 |
| 1000 Hz, <=20 DB HL: Month 24 | 6 | 6 |
| 1000 Hz, 21-40 DB HL: Month 24 | 4 | 3 |
| 2000 Hz, <=20 DB HL: Month 24 | 6 | 3 |
| 2000 Hz, 21-40 DB HL: Month 24 | 2 | 4 |
| 4000 Hz, <=20 DB HL: Month 24 | 5 | 4 |
| 4000 Hz, 21-40 DB HL: Month 24 | 4 | 3 |
Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with peak pressure signs (+) and (-) at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
| decapascals | IV Sildenafil | Placebo |
|---|---|---|
| Peak Pressure for Sign (+), Right Ear: Month 12 | 51.89 ± 63.024 | 27.33 ± 26.539 |
| Peak Pressure for Sign (+), Left Ear: Month 12 | 5.07 ± 4.900 | 73.75 ± 28.987 |
| Peak Pressure for Sign (+), Right Ear: Month 24 | 44.00 ± 46.130 | 33.50 ± 44.125 |
| Peak Pressure for Sign (+), Left Ear: Month 24 | 42.71 ± 50.112 | 35.00 ± 46.578 |
| Peak Pressure for Sign (-), Right Ear: Month 12 | 149.3 ± 144.34 | 67.75 ± 57.350 |
| Peak Pressure for Sign (-), Left Ear: Month 12 | 79.89 ± 64.367 | 46.80 ± 46.912 |
| Peak Pressure for Sign (-), Right Ear: Month 24 | 98.00 ± 55.685 | 83.67 ± 107.38 |
| Peak Pressure for Sign (-), Left Ear: Month 24 | 102.2 ± 84.781 | 135.0 ± 70.711 |
Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with static acoustic admittance at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
| millimho | IV Sildenafil | Placebo |
|---|---|---|
| Right Ear: Month 12 | 0.241 ± 0.1403 | 0.403 ± 0.1691 |
| Left Ear: Month 12 | 0.364 ± 0.1513 | 0.330 ± 0.1595 |
| Right Ear: Month 24 | 0.273 ± 0.0784 | 0.400 ± 0.1321 |
| Left Ear: Month 24 | 0.295 ± 0.0691 | 0.585 ± 0.5558 |
Audiological evaluations of participants were recorded and reported by ipsilateral stapedial reflex through immittance audiometry test which included participants with presence of ipsilateral stapedial reflex at frequencies ranged from 500 Hz to 2000 Hz at month 12 and 24. Ipsilateral stapedial reflex measures are used to assess the neural pathway surrounding the stapedial reflex, which occurs in response to a loud sound (70 to 90 decibel above threshold). In this outcome measure, data have been reported for right and left ear separately.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| 500 Hz, Right Ear: Month 12 | 5 | 1 |
| 500 Hz, Left Ear: Month 12 | 6 | 1 |
| 1000 Hz, Right Ear: Month 12 | 5 | 1 |
| 1000 Hz, Left Ear: Month 12 | 6 | 1 |
| 2000 Hz, Right Ear: Month 12 | 5 | 1 |
| 2000 Hz, Left Ear: Month 12 | 6 | 1 |
| 500 Hz, Right Ear: Month 24 | 4 | 2 |
| 500 Hz, Left Ear: Month 24 | 4 | 2 |
| 1000 Hz, Right Ear: Month 24 | 4 | 2 |
| 1000 Hz, Left Ear: Month 24 | 5 | 2 |
| 2000 Hz, Right Ear: Month 24 | 4 | 2 |
| 2000 Hz, Left Ear: Month 24 | 4 | 2 |
Audiological evaluations of participants were recorded and reported by transient evoked emission through otoacoustic emissions assessment which included participants with presence of transient evoked emissions from frequencies 1000 Hz to 4000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| 1000 Hz, Right Ear: Month 12 | 3 | 2 |
| 1000 Hz, Left Ear: Month 12 | 2 | 1 |
| 1500 Hz, Right Ear: Month 12 | 3 | 2 |
| 1500 Hz, Left Ear: Month 12 | 2 | 2 |
| 2000 Hz, Right Ear: Month 12 | 5 | 2 |
| 2000 Hz, Left Ear: Month 12 | 5 | 2 |
| 3000 Hz, Right Ear: Month 12 | 4 | 2 |
| 3000 Hz, Left Ear: Month 12 | 4 | 2 |
| 4000 Hz, Right Ear: Month 12 | 6 | 2 |
| 4000 Hz, Left Ear: Month 12 | 5 | 3 |
| 1000 Hz, Right Ear: Month 24 | 3 | 2 |
| 1000 Hz, Left Ear: Month 24 | 2 | 2 |
| 1500 Hz, Right Ear: Month 24 | 2 | 3 |
| 1500 Hz, Left Ear: Month 24 | 2 | 3 |
| 2000 Hz, Right Ear: Month 24 | 7 | 3 |
| 2000 Hz, Left Ear: Month 24 | 6 | 3 |
| 3000 Hz, Right Ear: Month 24 | 6 | 3 |
| 3000 Hz, Left Ear: Month 24 | 4 | 3 |
| 4000 Hz, Right Ear: Month 24 | 7 | 3 |
| 4000 Hz, Left Ear: Month 24 | 5 | 3 |
Audiological evaluations of participants were recorded and reported by distort product through otoacoustic emissions assessment which included participants with presence of distort product at frequencies ranged from 2000 Hz to 8000 Hz at month 12 and 24. Distortion-product otoacoustic emissions (DPOAEs) are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal. Distort product otoacoustic emissions are an objective indicator of normally functioning cochlea outer hair cells. In this outcome measure, data have been reported for right and left ear separately.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| 2000 Hz, Right Ear: Month 12 | 4 | 4 |
| 2000 Hz, Left Ear: Month 12 | 5 | 3 |
| 3000 Hz, Right Ear: Month 12 | 5 | 4 |
| 3000 Hz, Left Ear: Month 12 | 5 | 3 |
| 4000 Hz, Right Ear: Month 12 | 5 | 4 |
| 4000 Hz, Left Ear: Month 12 | 5 | 3 |
| 6000 Hz, Right Ear: Month 12 | 4 | 4 |
| 6000 Hz, Left Ear: Month 12 | 5 | 4 |
| 8000 Hz, Right Ear: Month 12 | 4 | 2 |
| 8000 Hz, Left Ear: Month 12 | 5 | 2 |
| 2000 Hz, Right Ear: Month 24 | 4 | 7 |
| 2000 Hz, Left Ear: Month 24 | 4 | 6 |
| 3000 Hz, Right Ear: Month 24 | 7 | 5 |
| 3000 Hz, Left Ear: Month 24 | 6 | 5 |
| 4000 Hz, Right Ear: Month 24 | 6 | 5 |
| 4000 Hz, Left Ear: Month 24 | 6 | 5 |
| 6000 Hz, Right Ear: Month 24 | 4 | 6 |
| 6000 Hz, Left Ear: Month 24 | 5 | 6 |
| 8000 Hz, Right Ear: Month 24 | 3 | 2 |
| 8000 Hz, Left Ear: Month 24 | 4 | 2 |
An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.
| Participants | IV Sildenafil | Placebo |
|---|---|---|
| AEs | 17 | 17 |
| SAEs | 9 | 6 |
| Deaths | 0 | 2 |
The Hammersmith Infant Neurological Examination (HINE) was a standard scoring examination to assess development of cranial nerve; posture; movement; tone; and reflexes and reaction. HINE exam global score is a sum of subset (cranial nerve, posture, movement, tone, reflexes and reactions) scores, ranged from 0 to 78, where higher score represents better outcome. Here, the HINE global scores were reported at month 12 and 24.
| units on a scale | IV Sildenafil | Placebo |
|---|---|---|
| Neurological Exam Global Score: Month 12 | 69.9 ± 14.97 | 75.6 ± 3.45 |
| Neurological Exam Global Score: Month 24 | 65.6 ± 19.71 | 76.5 ± 2.42 |
Collected over Part A: Baseline up to 31 days after end of study drug infusion (up to 45 days); Part B: up to 24 months after end of study treatment in Part A (maximum up to 26 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: IV Sildenafil | 2/29 (6.9%) | 7/29 (24.1%) | 20/29 (69%) |
| Part A: Placebo | 1/30 (3.3%) | 2/30 (6.7%) | 19/30 (63.3%) |
| Part B: IV Sildenafil | 0/27 (0%) | 9/27 (33.3%) | 14/27 (51.9%) |
| Part B: Placebo | 2/26 (7.7%) | 6/26 (23.1%) | 15/26 (57.7%) |
| Event | Part A: IV Sildenafil | Part A: Placebo | Part B: IV Sildenafil | Part B: Placebo |
|---|---|---|---|---|
| Respiratory syncytial virus infectionInfections and infestations | 0/29 | 0/30 | 2/27 | 3/26 |
| PneumoniaInfections and infestations | 0/29 | 0/30 | 2/27 | 0/26 |
| SeizureNervous system disorders | 1/29 | 0/30 | 0/27 | 1/26 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/29 | 0/30 | 0/27 | 1/26 |
| Viral upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/29 | 0/30 | 0/27 | 1/26 |
| Pulmonary hypertension crisisRespiratory, thoracic and mediastinal disorders | 0/29 | 0/30 | 0/27 | 1/26 |
| Oxygen saturation decreasedInvestigations | 0/29 | 0/30 | 0/27 | 1/26 |
| Congenital heart diseaseCongenital, familial and genetic disorders | 0/29 | 0/30 | 0/27 | 1/26 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 0/29 | 0/30 | 0/27 | 1/26 |
| Urinary tract infectionInfections and infestations | 0/29 | 0/30 | 0/27 | 1/26 |
| Event | Part A: IV Sildenafil | Part A: Placebo | Part B: IV Sildenafil | Part B: Placebo |
|---|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 7/29 | 0/30 | 0/27 | 0/26 |
| HypotensionVascular disorders | 7/29 | 3/30 | 1/27 | 1/26 |
| Ear infectionInfections and infestations | 0/29 | 0/30 | 4/27 | 0/26 |
| NasopharyngitisInfections and infestations | 0/29 | 0/30 | 4/27 | 3/26 |
| AnaemiaBlood and lymphatic system disorders | 4/29 | 3/30 | 1/27 | 2/26 |
| Drug withdrawal syndromeGeneral disorders | 4/29 | 0/30 | 0/27 | 0/26 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/29 | 4/30 | 0/27 | 1/26 |
| Otitis mediaInfections and infestations | 0/29 | 0/30 | 1/27 | 3/26 |
| BradycardiaCardiac disorders | 3/29 | 1/30 | 0/27 | 0/26 |
| OedemaGeneral disorders | 1/29 | 3/30 | 0/27 | 0/26 |
Safety population included all participants treated with study treatment.
| Age, Continuous(days) | IV Sildenafil | Placebo | Total |
|---|---|---|---|
| Mean | 1.7 ± 0.90 | 1.9 ± 0.75 | 1.8 ± 0.83 |
| Sex: Female, Male(Participants) | IV Sildenafil | Placebo | Total |
|---|---|---|---|
| Female | 13 | 13 | 26 |
| Male | 16 | 17 | 33 |
| Ethnicity (NIH/OMB)(Participants) | IV Sildenafil | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 3 |
| Not Hispanic or Latino | 23 | 29 | 52 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | IV Sildenafil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 5 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 7 | 8 |
| White | 19 | 16 | 35 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2013 to primary completion in Oct 2018, 62 months.
Results were first posted in Mar 2020, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Persistent Fetal Circulation Syndrome →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →